Sosei Heptares Turns To AI In GPCR-Focused Drug Discovery Pact
Duo Is Using AI To Identify GPCR Targets Across Multiple Disease Areas
Sosei Heptares hopes to create transformative therapeutics for immune diseases by combining its GPCR structure-based drug design and early development capabilities with InveniAI's already validated AI-based platform, its head of new target identification tells Scrip.
